New Form of Hypertonic Solution for Nebulization Therapy
https://doi.org/10.15690/vsp.v15i6.1662
Abstract
Mucolytic, expectorative and antitussive drugs are traditionally used in acute or chronic respiratory episodes affected by acute respiratory infections. Today, preference is given to drugs in a form of solutions for nebulization therapy. The article presents data on the new dosage form of 7% inhalation hypertonic solution in combination with hyaluronic acid used in mucostasis therapy for chronic respiratory diseases. The information on the properties and the favorable effect of hyaluronic acid is provided. We discuss the evidence base of inhalation of the hypertonic solution in combination with hyaluronic acid in cystic fibrosis.
About the Authors
Olga I. Simonova
Scientific Center of Children’s Health
Sechenov First Moscow State Medical University
Russian Federation
Moscow, Russian Federation
Russian Federation
Moscow, Russian Federation
Yulia V. Gorinova
Scientific Center of Children’s Health
Russian Federation
Moscow, Russian Federation
Russian Federation
Moscow, Russian Federation
References
1. Локшина Э.Э., Зайцева О.В., Зайцева С.В. Ингаляционная терапия респираторных заболеваний у детей // Атмосфера. Практическая пульмонология. — 2012. — № 4 — С. 41–45. [Lokshina EE, Zaitseva OV, Zaitseva SV. Ingalyatsionnaya terapiya respiratornykh zabolevanii u detei. Atmosfera. Pul’monologiya i allergologiya. 2012;(4):41–45. (In Russ)]
2. Мукоактивная терапия / Под ред. Чучалина А.Г., Белевского А.С. — М.: Атмосфера; 2006. — 124 с. [Mukoaktivnaya terapiya. Ed by Chuchalin A.G., Belevskii A.S. Moscow: Atmosfera; 2006. 124 p. (In Russ)]
3. Симонова О.И. Муколитики в педиатрической практике: рациональный выбор, лечебные эффекты и особенности терапии // Вопросы современной педиатрии. — 2013. — Т. 12. — № 4 — С. 136–141. [Simonova OI. Mucolytic agents in pediatrics: rational selection, therapeutic effects and specific aspects of treatment. Current pediatrics. 2013;12(4):136–141. (In Russ).] doi: 10.15690/vsp.v12i4.741.
4. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–240. doi: 10.1056/NEJMoa043900.
5. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997;52(10):900–903. doi: 10.1136/thx.52.10.900.
6. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–250. doi: 10.1056/NEJMoa043891.
7. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med. 2006;354(3):291–293. doi: 10.1056/NEJMe058293.
8. Патрушева Ю.С., Бакрадзе М.Д. Этиология и факторы риска острого бронхиолита у детей // Вопросы диагностики в педиатрии. — 2012. — Т. 4. — № 3 — С. 45–52. [Patrusheva YS, Bakradze MD. Etiology and risk factors of acute viral lower respiratory tract infections in young children. Pediatric diagnostics. 2012;4(3):45–52. (In Russ).]
9. Симонова О.И., Горинова Ю.В., Бакрадзе М.Д. Эффективность гипертонического раствора у детей с бронхитами и бронхиолитами // Вопросы современной педиатрии. — 2014. — Т. 13. — № 4 — С. 33–39. [Simonova OI, Gorinova YuV, Bakradze MD. Efficiency of hypertonic solution inhalation in children with bronchitis and bronchiolitis. Current pediatrics. 2014;13(4):33–39. (In Russ).] doi: 10.15690/vsp.v13i4.1082.
10. Buonpensiero P, De Gregorio F, Sepe A, et al. Hyaluronic acid improves ‘‘pleasantness’’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv Ther. 2010; 27(11):870–878. doi: 10.1007/s12325-010-0076-8.
11. Maiz Carro L, Lamas Ferreiro A, Ruiz de Valbuena M, et al. [Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis. (In Spanish).] Med Clin (Barc). 2012;138(2):57–59. doi: 10.1016/j.medcli.2011.02.022.
12. Pradal U, Borruso A, Salonini E, et al. Hyaluronic acid in the prevention of bronchial obstruction induced by hypertonic saline. J Cyst Fibros. 2010;9(Suppl 1):S62. doi: 10.1016/s1569-1993(10)60241-x.
13. Meyer K, Palmer JW. The polysaccharide of the vitreous humor. J Biol Chem. 1934;107:629–634.
14. Stern R. Devising a pathway for hyaluronan catabolism: are we there yet? Glycobiology. 2003;13(12):105R–115R. doi: 10.1093/glycob/cwg112.
15. Якимов Л.А., Найманн А.И., Текев И.А. Использование искусственной синовиальной жидкости при лечении остеоартроза // Кафедра травматологии и ортопедии. — 2013. — № 1 — С. 11–14. [Yakimov LA, Naimann AI, Tekeev IA. Ispol’zovanie iskusstvennoi sinovial’noi zhidkosti pri lechenii osteoartroza. Kafedra travmatologii i ortopedii. 2013; (1):11–14. (In Russ).]
16. Turino GM, Cantor JO. Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med. 2003;167(9):1169–1175. doi: 10.1164/rccm.200205-449PP.
17. Cantor JO, Turino JM. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004;125(1):288–292. doi: 10.1378/chest.125.1.288.
18. Cantor JO, Shteyngart B, Cerreta JM, et al. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med. 2000;225(1):65–71. doi: 10.1046/j.1525-1373.2000.22508.x.
19. Scuri M, Abraham WM. Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm Pharmacol Ther. 2003;16(6):335–340. doi: 10.1016/S1094- 5539(03)00089-0.
20. Furnari ML, Termini L, Traverso G, et al. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study. Ther Adv Respir Dis. 2012;6(6):315–322. doi: 10.1177/1753465812458984.
21. Ros M, Casciaro R, Lucca F, et al. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J Aerosol Med Pulm Drug Deliv. 2014;27(2):133–137. doi: 10.1089/jamp.2012.1034.
Review
For citations:
Simonova O.I., Gorinova Yu.V. New Form of Hypertonic Solution for Nebulization Therapy. Current Pediatrics. 2016;15(6):631-634. (In Russ.) https://doi.org/10.15690/vsp.v15i6.1662
Views:
1118
Email this article 
